Badar, Talha http://orcid.org/0000-0003-1548-918X
Nanaa, Ahmad http://orcid.org/0000-0001-5247-5065
Atallah, Ehab
Shallis, Rory M.
Guilherme, Sacchi de Camargo Correia
Goldberg, Aaron D.
Saliba, Antoine N. http://orcid.org/0000-0001-5134-7336
Patel, Anand http://orcid.org/0000-0002-0296-8686
Bewersdorf, Jan P. http://orcid.org/0000-0003-3352-0902
DuVall, Adam S.
Bradshaw, Danielle
Abaza, Yasmin http://orcid.org/0000-0002-9156-7912
Murthy, Guru Subramanian Guru
Palmisiano, Neil
Zeidan, Amer M.
Kota, Vamsi http://orcid.org/0000-0002-5290-9289
Litzow, Mark R.
Article History
Received: 2 January 2024
Revised: 6 February 2024
Accepted: 8 February 2024
First Online: 20 February 2024
Competing interests
: TB served in advisory board for Pfizer, Takeda and Morphosys. AP received research funding from Pfizer, Kronos Bio; Honoraria from AbbVie and Bristol Myers Squibb. ADG received research funding from AbbVie, Aprea, Aptose, AROG, Celularity, Pfizer, and Prelude; Consultancy and Advisory Boards with AbbVie, Astellas, Daiichi Sankyo; Honoraria from Dava Oncology. The other authors declare no competing interests.